Bio-Techne (TECH) Long-Term Deferred Tax (2010 - 2025)

Bio-Techne's (TECH) quarterly Long-Term Deferred Tax came in at $10.3 million in Q2 2025, up 1812.24% quarter-over-quarter from $539000.0 in Q1 2011.

Bio-Techne (TECH) Long-Term Deferred Tax (2010 - 2025) Analysis & Trends

Bio-Techne's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $10.3 million for Q2 2025.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $10.3 million in Q2 2025; TTM through Jun 2025 was $10.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.3 million, changed N/A from the prior year.
Long-Term Deferred Tax advanced to $10.3 million in Q2 2025 per TECH's latest filing, from $539000.0 in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $10.3 million in Q2 2025 and bottomed at $10.3 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Bio-Techne	11.23 Bn	11.02 Bn	208.29 Mn

Download Data